Kamada (Kamada) 14-Day RSI

: 36.43 (As of Today)

View and export this data going back to 2013. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-24), Kamada's 14-Day RSI is 36.43.

The industry rank for Kamada's 14-Day RSI or its related term are showing as below:

KMDA's 14-Day RSI is ranked better than
83.09% of 1141 companies
in the Drug Manufacturers industry
Industry Median: 46.48 vs KMDA: 36.43

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kamada 14-Day RSI Distribution

For the Drug Manufacturers industry and Healthcare sector, Kamada's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Kamada's 14-Day RSI falls into.

Kamada (NAS:KMDA) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI

100

–

[ 100

( 1 + Average Gain

Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kamada (NAS:KMDA) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

Kamada 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Kamada's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.

Kamada (Kamada) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » 14-Day RSI

Comparable Companies

Traded in Other Exchanges

KMDA:Israel

Address

2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402

Website

https://www.kamada.com

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.